Cerity Partners
LAB icon

Cerity Partners’s Standard BioTools LAB Stock Holding History

Cerity Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Buy
49,980
+5,919
+13% +$5.59K ﹤0.01% 3314
2026
Q1 		$40.5K Buy
44,061
+7,487
+20% +$9.06K ﹤0.01% 3127
2025
Q4 		$46.8K Sell
36,574
-14
-0% -$19 ﹤0.01% 2810
2025
Q3 		$47.6K Sell
36,588
-913
-2% -$1.2K ﹤0.01% 2703
2025
Q2 		$45K Buy
37,501
+15,470
+70% +$17.1K ﹤0.01% 2554
2025
Q1 		$23.8K Buy
+22,031
New +$30.9K ﹤0.01% 2444
2023
Q3 		– Sell
-12,588
Closed -$24.3K – 1572
2023
Q2 		$24.3K Hold
12,588
– – ﹤0.01% 1599
2023
Q1 		$24.5K Hold
12,588
– – ﹤0.01% 1820
2022
Q4 		$14.7K Buy
12,588
+182
+1% +$224 ﹤0.01% 1462
2022
Q3 		$13K Buy
12,406
+406
+3% +$614 ﹤0.01% 1168
2022
Q2 		$19K Sell
12,000
-100
-0.8% -$247 ﹤0.01% 1166
2022
Q1 		$43K Sell
12,100
-10
-0.1% -$35 ﹤0.01% 920
2021
Q4 		$47K Hold
12,110
– – ﹤0.01% 1002
2021
Q3 		$80K Hold
12,110
– – ﹤0.01% 672
2021
Q2 		$75K Buy
12,110
+10
+0.1% +$53 ﹤0.01% 700
2021
Q1 		$55K Buy
12,100
+100
+0.8% +$549 ﹤0.01% 686
2020
Q4 		$72K Hold
12,000
– – ﹤0.01% 633
2020
Q3 		$89K Sell
12,000
-11,257
-48% -$77.7K ﹤0.01% 490
2020
Q2 		$93K Buy
23,257
+2,000
+9% +$6.97K 0.01% 444
2020
Q1 		$54K Buy
+21,257
New +$69.8K ﹤0.01% 435
2019
Q4 		– Sell
-10,721
Closed -$50K – 556
2019
Q3 		$50K Sell
10,721
-10,721
-50% -$84.4K ﹤0.01% 470
2019
Q2 		$264K Buy
+21,442
New +$273K 0.02% 415

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's LAB Position: Q2 2026 in Review

Cerity Partners increased its Standard BioTools (LAB) stake by 13% in Q2 2026, buying an estimated $5.59K and bringing the position to 49,980 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3314.

Cerity Partners first reported a position in LAB in Q2 2019 and has held it in 22 quarters since. The position peaked at $264K in Q2 2019. 128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Cerity Partners held 49,980 shares of Standard BioTools worth $41.1K as of Q2 2026.
  • Cerity Partners bought 5,919 Standard BioTools shares in Q2 2026, an estimated $5.59K.
  • Standard BioTools made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3314 holding.
  • Cerity Partners first reported a position in Standard BioTools in Q2 2019 and has held it in 22 quarters since.
  • Cerity Partners's Standard BioTools position peaked at $264K in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.